Tangshen formula protects against podocyte apoptosis via enhancing the TFEB-mediated autophagy-lysosome pathway in diabetic nephropathy

• Published in: Journal of ethnopharmacology Vol. 324; p. 117721
• Main Authors: Wang, Yuyang, Peng, Liang, Lu, Xiaoguang, Zhang, Haojun, Zhao, Hailing, Zhao, Tingting, Yang, Liping, Mao, Huimin, Ma, Fang, Liu, Tongtong, Li, Ping, Zhan, Yongli
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 24.04.2024
• Subjects: Albuminuria - drug therapy; Albuminuria - metabolism; Albuminuria - prevention & control; Animals; Apoptosis; Autophagic flux; Autophagy; Diabetes Mellitus, Experimental - drug therapy; Diabetes Mellitus, Experimental - metabolism; Diabetic Nephropathies - drug therapy; Diabetic Nephropathies - metabolism; Diabetic Nephropathies - prevention & control; Diabetic nephropathy; Drugs, Chinese Herbal; Lysosome; Lysosomes - metabolism; Male; Mice; Podocyte apoptosis; Podocytes; Tangshen formula; Transcription factor EB; Diabetic nephropathy; Podocyte apoptosis; Tangshen formula; Transcription factor EB; Autophagic flux; Lysosome
• DOI: 10.1016/j.jep.2024.117721
• ISSN: 0378-8741

Diabetic nephropathy (DN) is the leading cause of end-stage kidney disease and currently there are no specific and effective drugs for its treatment. Podocyte injury is a detrimental feature and the major cause of albuminuria in DN. We previously reported Tangshen Formula (TSF), a Chinese herbal medicine, has shown therapeutic effects on DN. However, the underlying mechanisms remain obscure. This study aimed to explore the protective effect of TSF on podocyte apoptosis in DN and elucidate the potential mechanism. The effects of TSF were assessed in a murine model using male KKAy diabetic mice, as well as in advanced glycation end products-stimulated primary mice podocytes. Transcription factor EB (TFEB) knockdown primary podocytes were employed for mechanistic studies. In vivo and in vitro studies were performed and results assessed using transmission electron microscopy, immunofluorescence staining, and western blotting. TSF treatment alleviated podocyte apoptosis and structural impairment, decreased albuminuria, and mitigated renal dysfunction in KKAy mice. Notably, TSF extracted twice showed a more significant reduction in proteinuria than TSF extracted three times. Accumulation of autophagic biomarkers p62 and LC3, and aberrant autophagic flux in podocytes of DN mice were significantly altered by TSF therapy. Consistent with the in vivo results, TSF prevented the apoptosis of primary podocytes exposed to AGEs and activated autophagy. However, the anti-apoptosis capacity of TSF was countered by the autophagy–lysosome inhibitor chloroquine. We found that TSF increased the nuclear translocation of TFEB in diabetic podocytes, and thus upregulated transcription of its several autophagic target genes. Pharmacological activation of TFEB by TSF accelerated the conversion of autophagosome to autolysosome and lysosomal biogenesis, further augmented autophagic flux. Conversely, TFEB knockdown negated the favorable effects of TSF on autophagy in AGEs-stimulated primary podocytes. These findings indicate TSF appears to attenuate podocyte apoptosis and promote autophagy in DN via the TFEB-mediated autophagy-lysosome system. Thus, TSF may be a therapeutic candidate for DN. [Display omitted] •Tangshen Formula alleviates autophagic flux blockade in diabetic podocytes.•Autophagy contributes to the protective effects of Tangshen Formula against diabetic-induced podocyte apoptosis.•Tangshen Formula inhibits diabetic podocyte apoptosis via increasing the transcription factor EB-mediated autophagy-lysosome system.